William Blair Investment Management LLC cut its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,693,624 shares of the biopharmaceutical company’s stock after selling 29,064 shares during the period. William Blair Investment Management LLC’s holdings in PTC Therapeutics were worth $109,713,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in PTCT. BlackRock Inc. acquired a new stake in PTC Therapeutics in the 2nd quarter valued at approximately $1,139,089,000. Jupiter Topco LLC bought a new stake in PTC Therapeutics during the 2nd quarter valued at $590,182,000. Janus Henderson Group PLC raised its stake in PTC Therapeutics by 48.3% during the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after acquiring an additional 2,342,101 shares in the last quarter. Bank of America Corp DE bought a new stake in PTC Therapeutics during the 2nd quarter valued at $118,462,000. Finally, Jefferies Financial Group Inc. acquired a new position in PTC Therapeutics during the 2nd quarter worth $110,694,000.
Insiders Place Their Bets
In other news, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total transaction of $781,920.00. Following the completion of the transaction, the director owned 22,500 shares in the company, valued at approximately $1,466,100. This trade represents a 34.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 435 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total transaction of $27,909.60. Following the completion of the transaction, the vice president directly owned 105,272 shares in the company, valued at $6,754,251.52. This represents a 0.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 64,265 shares of company stock worth $4,412,399. 5.30% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the company. Raymond James Financial set a $106.00 price target on PTC Therapeutics in a research note on Tuesday, October 20th. Cantor Fitzgerald lifted their price objective on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Royal Bank Of Canada upped their price objective on shares of PTC Therapeutics from $75.00 to $77.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. Barclays upped their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Finally, Truist Financial initiated coverage on shares of PTC Therapeutics in a research report on Friday, October 16th. They issued a “hold” rating and a $62.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $99.23.
Check Out Our Latest Report on PTC Therapeutics
PTC Therapeutics Stock Performance
Shares of NASDAQ PTCT opened at $63.49 on Monday. The stock has a fifty day moving average price of $64.12 and a two-hundred day moving average price of $70.27. The firm has a market cap of $5.30 billion, a P/E ratio of -45.35, a PEG ratio of 4.66 and a beta of 0.52. PTC Therapeutics, Inc. has a 1 year low of $58.80 and a 1 year high of $90.87.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The firm had revenue of $357.81 million during the quarter, compared to the consensus estimate of $306.43 million. During the same quarter in the previous year, the company earned $0.20 earnings per share. The business’s quarterly revenue was up 69.6% on a year-over-year basis. On average, research analysts predict that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current fiscal year.
PTC Therapeutics announced that its Board of Directors has approved a share repurchase plan on Tuesday, November 3rd that authorizes the company to repurchase $500 million in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to repurchase up to 9.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.
PTC Therapeutics Company Profile
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Featured Stories
- Five stocks we like better than PTC Therapeutics
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report).
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
